- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 20, 2023
Highlights
- Market Cap
- $6.23M
- Enterprise Value
- $2.22M
- EPS (TTM)
- -$5.05
- Gross Profit (TTM)
- -$5.92K
- EBITDA (TTM)
- -$13.32M
- Year Range
- $1.86 - $14.64
- Target Price
- $32.00
- ROA (TTM)
- -235.71%
- ROE (TTM)
- -372.38%
- Avg. Volume (1M)
- 68K
- Avg. Volume Value (1M)
- $169.96K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CVKD Performance Chart
Cadrenal Therapeutics Inc. Common Stock (CVKD) is down 70.4% since the beginning of the year. At $2 per share, CVKD is trading 86.3% below its 52-week high of $15.
Loading charts...
Compare this symbol against anything
Returns By Period
Cadrenal Therapeutics Inc. Common Stock (CVKD) has returned -70.35% so far this year and -80.54% over the past 12 months.
Cadrenal Therapeutics Inc. Common Stock
- 1D
- -3.83%
- 1M
- -44.17%
- 6M
- -71.08%
- YTD
- -70.35%
- 1Y
- -80.54%
- 3Y*
- -46.42%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -65.49%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CVKD Monthly Returns History
Based on dividend-adjusted daily data since Jan 20, 2023, CVKD's average daily return is -0.22%, while the average monthly return is -2.88%.
Historically, 35% of months were positive and 65% were negative. The best month was Jan 2024 with a return of +146.0%, while the worst month was Feb 2024 at -61.3%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CVKD closed higher 45% of trading days. The best single day was Dec 28, 2023 with a return of +32.4%, while the worst single day was Dec 16, 2025 at -32.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.51% | 22.16% | -39.69% | 30.27% | -25.64% | -32.66% | -39.82% | -70.35% | |||||
| 2025 | 36.44% | -3.89% | -7.21% | -6.86% | -18.82% | -9.60% | -13.53% | 24.38% | 6.71% | -1.19% | -31.30% | -27.78% | -53.21% |
| 2024 | 145.98% | -61.32% | -13.35% | -27.87% | 7.11% | -0.28% | -7.64% | 16.95% | 79.25% | 24.25% | -10.44% | -4.61% | 30.56% |
| 2023 | -51.31% | -28.42% | -29.15% | -4.96% | 5.97% | 6.34% | -43.71% | -9.41% | -11.68% | -35.16% | 4.31% | 60.85% | -87.04% |
Benchmark Metrics
Cadrenal Therapeutics Inc. Common Stock has an annualized alpha of -52.19%, beta of 0.96, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since January 20, 2023.
- This stock participated in 369.05% of S&P 500 Index downside but only -58.85% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -52.19%
- Beta
- 0.96
- R²
- 0.02
- Upside Capture
- -58.85%
- Downside Capture
- 369.05%
Return for Risk
Risk / Return Rank
CVKD ranks 6 for risk / return — above 6% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Cadrenal Therapeutics Inc. Common Stock (CVKD) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CVKD | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.22 | ||
| Sortino ratioReturn per unit of downside risk | -3.59 | ||
| Omega ratioGain probability vs. loss probability | 0.82 | 1.25 | -0.43 |
| Calmar ratioReturn relative to maximum drawdown | -0.94 | 2.00 | -2.94 |
| Martin ratioReturn relative to average drawdown | -1.61 | 8.49 | -10.10 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cadrenal Therapeutics Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cadrenal Therapeutics Inc. Common Stock was 97.70%, occurring on Jul 29, 2026. The portfolio has not yet recovered.
The current Cadrenal Therapeutics Inc. Common Stock drawdown is 97.65%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-97.70%Jul 2026 | 3y 6mo | — | 3y 6moJan 2023 - now | — |
Drawdown Indicators
| CVKD | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.70% | -56.78% | -40.92% |
Max Drawdown (1Y)Largest decline over 1 year | -86.13% | -9.10% | -77.03% |
Max Drawdown (3Y)Largest decline over 3 years | -92.78% | -18.90% | -73.88% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.65% | -1.58% | -96.07% |
Average DrawdownAverage peak-to-trough decline | -85.16% | -10.70% | -74.46% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 50.14% | 2.14% | +48.00% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cadrenal Therapeutics Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cadrenal Therapeutics Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CVKD in comparison with other companies in the Biotechnology industry. Currently, CVKD has a P/B value of 1.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CVKD
Add Cadrenal Therapeutics Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CVKD